AstraZeneca Pharma India Reports 33% YoY Revenue Growth
Verified article - details checked for accuracy.
Data Extracted via Frism DocuLens
- Total revenue from operations: ₹ 22,755.8 Mn for FY 2025‑26, up 33 % YoY, driven by strong performance in Oncology, Biopharmaceuticals and Rare Disease segments.
- Profit after exceptional items & tax (PAT): ₹ 1,875.2 Mn for the year, reflecting disciplined execution and margin expansion.
- Quarter‑end snapshot (Q4 2026): Revenue ₹ 5,786.1 Mn; PAT ₹ 448.8 Mn.
- Operating profitability: Both pre‑tax and post‑tax profits rose sharply year‑on‑year, indicating improved operating margins despite no specific margin percentages disclosed.
- Therapy‑area revenue mix (FY 2025‑26):
- Oncology – ₹ 16,100.9 Mn
- Biopharmaceuticals (CVRM, R&I, V&I) – ₹ 5,243.2 Mn
- Rare Disease – ₹ 214.6 Mn
- Regulatory milestones: 11 new approvals in FY 2025‑26, adding products such as Durvalumab (multiple cancer indications), Eculizumab (aHUS, PNH), Osimertinib (expanded NSCLC uses), Trastuzumab deruxtecan (HER2‑low breast cancer), Benralizumab (EGPA), and Sodium Zirconium Cyclosilicate (hyperkalaemia). These approvals broaden the company’s therapeutic portfolio and reinforce its market leadership.
Complete ArticleExclusive Frism Intelligence Report
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.
Proudly crafted in India 🇮🇳
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka